Skip to main content

Advertisement

Table 2 Clinical response to the DC vaccine

From: The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer

  3 months 6 months
Clinical response All patients Alb ≥ 4.0 Alb < 4.0 All patients Alb ≥ 4.0 Alb < 4.0
  N % N % N % N % N % N %
CR 0 0 0 0 0 0 0 0 0 0 0 0
PR 2 3.6 2 5.5 0 0 1 1.8 1 2.8 0 0
SD 14 25 11 30.6 3 15 7 12.5 5 13.9 2 10
PD 32 57.1 19 52.8 13 65 42 75 27 75 15 75
NE 8 14.3 4 11.1 4 20 6 10.7 3 8.3 3 15
Total 56 100 36 100 20 100 56 100 36 100 20 100
ORR* 2 3.6 2 5.5 0 0 1 1.8 1 2.8 0 0
DCR** 16 28.6 13 36.1 3 15 8 14.3 6 16.7 2 10
  1. *Objective response rate (ORR), considers CR and PR.
  2. **Disease control rate (DCR), considers CR, PR, and SD.